

PUBLIC HEALTH ALERT

Issued: June 14, 2024

For: Washington State Hospital Emergency Departments and Emergency Medical Services
Contact WAPC, 24/7/365, by calling **1 (800) 222-1222** Media contact: mryuk@wapc.org

Severe illness potentially associated with Diamond Shruumz™ products

Multiple poison control centers across the United States, as well as the CDC and FDA, have received reports of severe acute illnesses and other adverse effects following consumption of Diamond Shruumz™ brand chocolate bars, cones, and gummies. These mushroom-containing edible products can be purchased online and may have been sold in Washington in person at a variety of retail locations, including smoke/vape shops and at retailers that sell hemp-derived products.

As of June 11, 2024, America's Poison Centers are aware of 12 patients who consumed Diamond Shruumz™ brand products and sought medical attention. To date, there have been no cases of severe illness associated with this product reported in Washington State. However, **cases of illness with other brands of mushroom-containing chocolate bars have been reported in Washington.** The cause of the reported illnesses is not known at this time. CDC, FDA, America's Poison Centers, Washington Poison Center, and Washington DOH are continuing to monitor cases of illness reported to poison centers. **Report any suspected cases or adverse effects after consuming any Diamond Shruumz™ brand products to the Washington Poison Center at 1-800-222-1222.**

Recommendations for clinicians

- Have a high index of suspicion for severe illness in any patient who recently consumed any of these products presenting to a healthcare facility with any of the clinical effects listed below
- Collect detailed information about the product(s) consumed, including the name of the product, type of product (e.g., chocolate, gummies), flavor(s), date(s) and location(s) of purchase, date(s) consumed
- Obtain early consultation with the Washington Poison Center: 1-800-222-1222
- Institute early supportive care and routine diagnostic testing
- Consider consulting a neurologist for evaluation and further diagnostic workup such as electroencephalogram (EEG) or imaging studies if there is any concern for status epilepticus
- Retain blood and urine samples for further testing

Management of suspected cases

Onset:

< 60 minutes

Duration:

Hours to days

Clinical Effects:

- Tachycardia
- Bradycardia
- Hypotension
- Hypertension
- Anxiety/agitation
- Hallucinations
- Seizures
- Coma

Labs & Monitoring:

- ABC's, IVF, EKG monitor
- Core temperature
- CMP, Phos, Mag, CPK
- Urine drug screen
- Blood alcohol

For more information, please see the [CDC Health Advisory](#). Follow investigation updates at [fda.gov](https://www.fda.gov).